NEOGENOMICS INC
Ticker: NEOIndustrialsProfessional ServicesThe business
NeoGenomics, Inc. (Nasdaq: NEO) is a leading provider of oncology diagnostic testing and consultative services operating a network of cancer-focused testing laboratories across the United States and the United Kingdom. The company's website is www.neogenomics.com.
The company operates a comprehensive range of cancer diagnostic services designed to complement the work of community-based pathologists, oncologists, and other healthcare providers. NeoGenomics offers cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry with digital imaging, molecular residual disease testing, molecular testing, and morphologic analysis. The company serves a diverse client base including community-based pathology and oncology practices, hospital pathology laboratories, reference laboratories, academic centers, and pharmaceutical companies.
NeoGenomics operates under a single reportable segment encompassing all service offerings. Revenue streams include clinical cancer testing, interpretation and consultative services, molecular and next-generation sequencing testing, molecular residual disease testing, third-party clinical trials and research support services, validation laboratory services, and oncology data solutions. The company's payer mix consists of approximately 71 percent client direct billing, 16 percent commercial insurance, and 13 percent Medicare and other government sources.
As of December 31, 2025, NeoGenomics employed approximately 2,500 full-time equivalent employees, including contracted pathologists, with approximately 135 MDs and PhDs on staff or under contract. The company operates College of American Pathologists accredited and Clinical Laboratory Improvement Amendments certified laboratories in Fort Myers, Florida; Aliso Viejo and Carlsbad, California; Durham, North Carolina; Ramsey, New Jersey; and Houston, Texas, along with an International Organization for Standardization certified laboratory in Cambridge, United Kingdom.
The company's competitive strengths include rapid turnaround times for test results, a comprehensive oncology-focused test menu including proprietary panels such as PanTracer and Neo Comprehensive offerings, a national direct sales force organized into ten regional territories, and a distinguished medical and scientific team. NeoGenomics acquired Inivata in June 2021, enhancing its capabilities with oncology liquid biopsy technology including RaDaR for molecular residual disease detection in solid tumor patients.
- Sector
- Industrials
- Industry
- Professional Services
- HQ
- FORT MYERS, FL
- FY end
- 12-31
- CIK
- 1077183
- SIC
- 8734
Ownership
Who holds NEOGENOMICS INC — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30
Top fund holders
| Fund | % of fund | Value |
|---|---|---|
| First Trust NYSE Arca Biotechnology Index Fund FBT · First Trust Exchange-Traded Fund | 5.12% | $144.00M |
| iShares Core S&P Small-Cap ETF IJR · iShares Trust | 0.10% | $114.48M |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI · VANGUARD INDEX FUNDS | 0.00% | $60.35M |
| iShares Russell 2000 ETF IWM · iShares Trust | 0.06% | $49.75M |
| VANGUARD SMALL-CAP INDEX FUND VB · VANGUARD INDEX FUNDS | 0.02% | $43.56M |
Bonds held by funds
Funds report holding 1 issues of NEOGENOMICS INC's debt, $0.56M at fund-held market value — what funds hold, not the company's debt outstanding. Weighted-average coupon 0.75%, maturing 2032–2032.
| Issue | Coupon | Matures | Funds | Fund-held |
|---|---|---|---|---|
| NeoGenomics Inc | 0.750% | 2032-07-01 | 3 | $0.56M |
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Go deeper in your own AI
15 years of statements, narrative and filings — queryable over MCP.
Professionals can also use the built-in AI chat (subscription + your own Anthropic key).
15 years of NEOGENOMICS INC's financials
Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.
Sign in free